News

Approval has been obtained from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human trial for EBC-129 in patients with solid tumours EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) that is entering clinical development. It is able to selectively target cancer cells across a range of solid tumours. The ADC and the […]

XtalPi joins hands with Singapore’s national platform for drug discovery and development to discover more effective treatment options for cancer patients worldwide. In this collaboration, XtalPi will leverage its quantum physics and AI-driven platform, while EDDC provides valuable insight and data on the novel NSCLC target, to accelerate the drug discovery process and propel the

Virtual screening involves the use of in silico methods to screen for potential small molecule binders of a target protein. This process usually starts with computationally docking a virtual library of chemical compounds to assess how the compounds interact with a defined binding site on the target protein. This is followed by scoring to predict

Minister for Trade and Industry, Mr Gan Kim Yong, creating an entry on the computer to insert a 384-well plate into the compound store at EDDC’s High Throughput Screening (HTS) facility.On 19 August 2022, Experimental Drug Development Centre (EDDC) hosted a visit by Minister for Trade and Industry, Mr Gan Kim Yong. This visit was

The World Health Organisation1 estimates that over 1.5 million people die from tuberculosis (TB) worldwide, making it the second leading infectious disease killer after COVID-19. Caused by the bacterium Mycobacterium tuberculosis, TB is an infectious disease that has plagued humankind for more than 70,000 years2, with an estimated 10 million new cases of TB annually.

EDDC’s Biomarker team analysing samples from ETC-159 trialA made-in-Singapore cancer drug, ETC-159, has advanced into the dose expansion portion of its Phase 1B clinical trial. The Phase 1B dose expansion study tests the preliminary efficacy and safety of ETC-159 in a subset of genetically defined patients with microsatellite stable (MSS)1 cancers. MSS tumours have few

The following text is adapted from this press release. EDDC staff planning the automation of an antibody engineering process. Boehringer Ingelheim gains exclusive global rights to a panel of cancer-specific antibodies to enable the development of targeted cancer therapies These engineered antibodies may allow for specific targeting of tumor cells without binding to healthy cells

In 2018, local biotech start-up AUM Biosciences (AUM) was looking to kick-off an “Asia to Global” vision through a focus on developing therapeutics for Asia-Pacific cancers, which could also be delivered to Western markets. That year, the oncology research company licensed ETC-206, now known as AUM001, a MNK inhibitor that was developed by a legacy

Everest gains exclusive global rights to a series of 3CL protease inhibitors to treat COVID-19 Everest will have sub-licensing rights and full technology transfer Licensing of 3CL protease inhibitor oral treatment is expected to complement Everest’s COVID-19 vaccine program Clinical trials evaluating lead asset EDDC-2214 expected to start later this year Shanghai, China — January

This is an excerpt of an article in Duke-NUS Medicus 2021 issue 4. The (Wnt)ing way: Fighting cancer with ETC-159Wnts, which instruct cells on what they should become, are only found in multicellular animals, but not in single cell organisms such as yeast or amoebas, which don’t have as much need for proteins that communicate